In recent years, both ex vivo and in vivo gene therapy strategies to treat VWD have been investigated, trying to overcome limitations related to the large size of the VWF cDNA (8.4 kb) and the VWF transient expression [15–19]. This evidence concerns the gene VWF and von Willebrand disease (hereditary or acquired).